




**Figure 1**


**FIGURE 2**

3/21


**FIGURE 3**

4/21







**FIGURE 4**  
**Protocols used to evaluate drugs**  
**in the rat CIA (COL-II) and AIA (*Mtb*) models**



5/21

**FIGURE 5**

6/21


**FIGURE 6**

7/21


## FIGURE 7

## RAT CIA TOLERAGENIC PROTOCOL DAY 15

Control ChS(20mg/kg) CaP(10mg/kg) Coll-II(10mg/kg)



8/21

**FIGURE 8****RAT CIA PROPHYLACTIC PROTOCOL DAY 15****■ Control ■ GmSO4(200mg/kg) □ GmHCl(200mg/kg) ■ CaP(20mg/kg)**




9/21

## FIGURE 9


## RAT CIA TOLERAGENIC PROTOCOL DAY 15

▨ Controls    ▨ CaP(20mg/kg)    ■ GAG-P(20mg/kg)



10/21.

FIGURE 10




11/21

## FIGURE 11


## RAT CIA PROPHYLACTIC PROTOCOL DAY 15

■ Control □ CaP(3.3mg/kg) ▨ CaP(10mg/kg) ▩ CaP(20mg/kg) ■ CaP(200mg/kg)




12/21

## FIGURE 12



**FIGURE 13**


**RAT CIA PROPHYLACTIC PROTOCOL DAY 18**



14/21

## FIGURE 14

## RAT CIA PROPHYLACTIC PROTOCOL DAY 15




15/21

## FIGURE 15

## RAT AIA PROPHYLACTIC PROTOCOL DAY 15

▨ Controls   ▨ CaP(20mg/kg)   ▨ CaP(200mg/kg)   ▨ GAG-P(20mg/kg)




16/21

## FIGURE 16

## RAT AIA PROPHYLACTIC PROTOCOL DAY 18


▨ Controls ■ CaP(20mg/kg) ▤ CaP(200mg/kg) ■ GAG-P(20mg/kg)





17/21

FIGURE 17



18/21

**TABLE 1**

**Gastroprotective activity of Calcium Peptacan (CaP) in the Rat CIA Arthritis Model against haemorrhagic stomach lesions produced by oral administration of the non-steroidal anti-inflammatory drug, Ibuprofen (Nurofen®) (50 mg/kg) on day 20. In this model arthritis is manifest by day 15**

<b>Treatment</b>	<b>Period of treatment (days)</b>	<b>Mean number of lesions</b>	<b>Number of Rats</b>
Nil		25	7
CaP (20mg/kg/day, orally)	0-15	4	3
CaP (200mg/kg/day, orally)	0-15	9	3
CaP (200mg/kg/day, orally)	17-20	7	4
Aurothiomalate (6.3mg/kg, s.c.)	Days 1,3,5,7,9,11,13,15	14	2
Non-arthritic controls nil treatment	Nil	2	5

19/21

**TABLE 2: Topical anti-inflammatory activity of Cream base with and without the addition of the Glycosaminoglycan preparation, GAG-PLH prepared by limited hydrolysis of cartilage. Decrease of Sodium Lauryl Sulfate induced erythema determined from difference on day 1 (t=1) to day 8 (t=8). In 8 of 10 subjects Cream base + GAG-PLH showed lower scores than Cream base alone demonstrating higher anti-inflammatory activity with GAG-PLH.\***

Test Subject No: 7055

Left Arm		Cream Base		Right Arm		Cream Base + GAG-PLH	
t=1	2	t=1	2	t=1	3	t=1	2
t=2	0	t=2	1	t=2	0	t=2	1
t=3	0	t=3	1	t=3	0	t=3	1
t=4	0	t=4	1	t=4	0	t=4	1
Mean Change: t=1 to t=4		-1.0		Mean Change: t=1 to t=4		-2.0	

Test Subject No: 7081

Left Arm		Cream Base		Right Arm		Cream Base + GAG-PLH	
t=1	2	t=1	3	t=1	3	t=1	4
t=2	1	t=2	2	t=2	2	t=2	3
t=3	1	t=3	2	t=3	2	t=3	2
t=4	1	t=4	2	t=4	2	t=4	2
Mean Change: t=1 to t=4		-1.5		Mean Change: t=1 to t=4		-1.8	

Test Subject No: 7089

Left Arm		Cream Base + GAG-PLH		Right Arm		Cream Base	
t=1	3	t=1	4	t=1	4	t=1	4
t=2	0	t=2	1	t=2	0	t=2	2
t=3	0	t=3	1	t=3	0	t=3	1
t=4	0	t=4	1	t=4	0	t=4	1
Mean Change: t=1 to t=4		-3.0		Mean Change: t=1 to t=4		-2.7	

Test Subject No: 7463

Left Arm		Cream Base		Right Arm		Cream Base + GAG-PLH	
t=1	3	t=1	4	t=1	5	t=1	6
t=2	3	t=2	3	t=2	4	t=2	5
t=3	1	t=3	2	t=3	3	t=3	4
t=4	1	t=4	1	t=4	2	t=4	3
Mean Change: t=1 to t=4		-3.0		Mean Change: t=1 to t=4		-3.3	

20/21

TABLE 2 Continued

Test Subject No. 173

Left Arm		Cream Base + GAG-PLH		Right Arm		Cream Base	
t=1	+1	2	4	1	2	3	5
t=2	+1	2	4	2	1	4	4
t=3	+1	3	3	2	2	1	3
t=4	0	0	+1	0	0	1	3
Mean Change: t=1 to t=4		-3.3		Mean Change: t=1 to t=4		-2.8	

Test Subject No. 180

Left Arm		Cream Base + GAG-PLH		Right Arm		Cream Base	
t=1	1	3	5	1	2	4	4
t=2	1	3	5	2	1	4	4
t=3	1	3	4	2	1	3	3
t=4	7	2	1	0	1	2	2
Mean Change: t=1 to t=4		-2.3		Mean Change: t=1 to t=4		-2.3	

Test Subject No. 336

Left Arm		Cream Base		Right Arm		Cream Base + GAG-PLH	
t=1	+1	2	4	1	2	3	5
t=2	2	4	4	2	1	4	4
t=3	2	2	+1	2	2	1	3
t=4	0	1	1	0	0	+1	2
Mean Change: t=1 to t=4		-2.5		Mean Change: t=1 to t=4		-2.8	

Test Subject No. 328

Left Arm		Cream Base		Right Arm		Cream Base + GAG-PLH	
t=1	2	4	3	1	2	3	5
t=2	0	2	4	2	1	4	4
t=3	0	7	1	2	2	1	3
t=4	0	0	0	0	0	0	3
Mean Change: t=1 to t=4		-3.8		Mean Change: t=1 to t=4		-3.8	

TABLE 2 Continued

[illegible]

## •ERYTHEMA SCORING SYSTEM

**One hour after removal of all patches and before application of the topical medications all sites were evaluated for response using the scoring and corresponding numerical value shown below:**

## SCORE

- 0 = no evidence of an effect  
? = query

- 1 = minimal, faint, uniform or spotty erythema  
 1 = pink uniform erythema covering most or all of the contact site  
 2 = pink-red erythema visibly uniform over entire contact site  
 3 = bright red erythema with or without petechias or papules  
 4 = deep red erythema with or without vesiculation or weeping

**The same evaluation was completed at each subsequent time point (t), that is 2, 4, and 8 days after initial application on day 1.**